MedPath

DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
🇯🇵Japan
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1
Active, not recruiting
Conditions
Breast Cancer
Non-small Cell Lung Carcinoma
Interventions
First Posted Date
2019-08-02
Last Posted Date
2025-02-24
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
115
Registration Number
NCT04042701
Locations
🇺🇸

Univ. of Cali. San Francisco Medical Center, San Francisco, California, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Cancer Specialists of North Florida (Cbo), Jacksonville, Florida, United States

and more 27 locations

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

Completed
Conditions
Baseline Epidemiologic Assessment
Interventions
Drug: MorphaBond ER
Drug: Comparator Drug
First Posted Date
2019-07-25
Last Posted Date
2021-03-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
17566
Registration Number
NCT04033094
Locations
🇺🇸

Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Phase 1
Completed
Conditions
Mineralocorticoid Receptor Antagonist
Hypertension
Interventions
First Posted Date
2019-07-15
Last Posted Date
2019-07-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
55
Registration Number
NCT04019652
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2
Completed
Conditions
Adenocarcinoma Gastric Stage IV With Metastases
Adenocarcinoma - GEJ
Interventions
First Posted Date
2019-07-10
Last Posted Date
2025-04-03
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
79
Registration Number
NCT04014075
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

USC Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States

🇺🇸

Pacific Cancer Care, Monterey, California, United States

and more 33 locations

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Treatment A - 400 mg Fasting
Drug: Treatment B - 400 mg Fed
Drug: Treatment C - 200 mg Fed
First Posted Date
2019-04-03
Last Posted Date
2020-05-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
24
Registration Number
NCT03901313
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Intrathecal (IT) triple chemotherapy prophylaxis
First Posted Date
2019-01-04
Last Posted Date
2025-01-17
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
65
Registration Number
NCT03793478
Locations
🇺🇸

Loma Linda University Cancer Center, Loma Linda, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

and more 24 locations

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Conditions
Acute Myeloid Leukemia With Gene Mutations
First Posted Date
2018-11-20
Last Posted Date
2020-04-15
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT03746912

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

First Posted Date
2018-11-07
Last Posted Date
2024-04-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
557
Registration Number
NCT03734029
Locations
🇺🇸

Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States

and more 205 locations

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

Phase 1
Completed
Conditions
Drug Pharmacokinetics in Healthy Volunteers
Interventions
First Posted Date
2018-10-09
Last Posted Date
2019-02-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
24
Registration Number
NCT03699774
Locations
🇺🇸

Worldwide Clinical Trials (WCT) Early Phase Services, San Antonio, Texas, United States

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Early Phase 1
Completed
Conditions
Food Effects on Pharmacokinetics
Interventions
First Posted Date
2018-08-27
Last Posted Date
2019-02-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
18
Registration Number
NCT03647202
Locations
🇺🇸

Covance Clinical Research Unit, Inc., Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath